Axsome Therapeutics stock rating reiterated by Cantor Fitzgerald

Investing.com - Cantor Fitzgerald has reiterated an Overweight rating and $153.00 price target on Axsome Therapeutics (NASDAQ:AXSM) following the company’s R&D Day.

The research firm highlighted Axsome’s deep portfolio of central nervous system (CNS) focused assets, including Auvelity (AXS-05), Sunosi (solriamfetol), Symbravo (AXS-07), AXS-12, and AXS-14, which were presented with key opinion leader perspectives. The company’s portfolio has driven impressive revenue growth of 72% and maintains industry-leading gross margins of 91%.

Cantor Fitzgerald noted that Axsome continues to execute on development and create value, with two regulatory submissions expected in the second half of 2025, multiple late-stage trial initiations in 2025, and two Phase 3 readouts anticipated in 2026.

The firm specifically pointed to "pipeline-in-a-product" candidates that provide market expansion opportunities, with AXS-05 and solriamfetol having potential to address multiple sizable indications with unmet needs.

Axsome’s R&D Day showcased the company’s CNS-focused pipeline strategy and upcoming catalysts that support Cantor Fitzgerald’s maintained Overweight rating and price target.

In other recent news, Axsome Therapeutics is preparing to host its Frontiers in Brain Health R&D Day on July 21, 2025, in New York City. The event will highlight the company’s late-stage central nervous system pipeline, featuring discussions by key opinion leaders and management overviews of clinical development programs. Mizuho (NYSE:MFG) has reiterated its Outperform rating for Axsome, setting a price target of $180.00 after the company’s Brain Health R&D Day event, emphasizing the company’s growing influence in CNS treatments. Similarly, Morgan Stanley (NYSE:MS) has assumed coverage with an Overweight rating and a $190.00 price target, focusing on Axsome’s supplemental New Drug Application filing for AXS-05 in Alzheimer’s disease agitation and the commercial launch of Auvelity for major depressive disorder. Piper Sandler also maintained an Overweight rating with a $148 price target, despite the FDA issuing a Refuse to File letter for Axsome’s New Drug Application for AXS-14, intended for fibromyalgia treatment. The FDA requested a confirmatory Phase III trial for AXS-14, as a smaller Phase II trial was deemed inadequate. These developments reflect Axsome’s ongoing efforts in advancing its CNS portfolio and addressing regulatory challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.